VBI Vaccines Inc. recently released new data that shows positive results from its glioblastoma multiforme cancer immunotherapy program.
The poster presentation, titled CMV gB/PP65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine against GMB, offered a summary about the latest progress the company has made in developing a therapeutic glioblastoma vaccine.
The latest developments feature new manufacturing characterization data, which verify the high quality as well as purity of the new vaccine candidate.
“We are encouraged by our preclinical data and by the quality of the vaccine candidate now being manufactured at a GMP-compliant facility,” Dr. David Anderson, VBI chief scientific officer, said. “We expect that purity measurements will meet regulatory requirements for clinical evaluation. We are planning to have a pre-IND meeting with the FDA in the first half of 2016 to discuss our plans to evaluate the vaccine in glioblastoma patients.”
The program at VBI emphasizes ex vivo studies, which suggest that the vaccine candidate is able to generate anti-tumor immunity within peripheral blood mononuclear cells. These cells are originally collected from health subjects as well as GBM patients.
The data was presented at the Keystone Symposia Cancer Vaccines Conference, which was hosted in Whistler, British Columbia, Canada. This peer-reviewed conference gathers leaders from the health industry and academia in order to exchange ideas about the field.
